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Abstract
Background: Cardiorenal syndrome type 2 is an “umbrella” term used to describe clinical conditions in which chronic cardiac failure through a 
chronological and causal relationship leads to renal dysfunction.  The syndrome is associated with a significant morbidity and mortality, that is why it has 
recently become a matter of growing debate related to pathogenesis, diagnosis, treatment effectiveness and safety.  Our aim was to review epidemiological 
and pathological mechanisms underlying cardiorenal syndrome, to focus on up-to-date diagnosis and treatment strategies.  We performed literature 
search in the Pubmed database in July 2015.  The 1st key word used for search was “cardiorenal syndrome type 2”; and the 2nd key word was “cardiorenal 
syndrome in heart failure”. 
Conclusions: Over the last decade, a significant advance in the understanding of the cardiorenal syndrome has been achieved.  However, precise pathways 
remain to be clarified.  Clinical management of these patients include diuretics, vasodilatators, ultrafiltration, all these modalities promise more rapid 
volume removal, but their ultimate impact on survival and renal function is unknown.  Future research is necessary to improve diagnosis, severity grading, 
to differentiate type 2 and type 4 cardiorenal syndrome and to determine efficient treatment strategies.  Because of the syndrome’s complexity and poor 
outcome, it is important that cardiologists, nephrologists and internists work together for a unique goal – protecting the patient with cardiorenal syndrome.
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Introduction
Many organ systems are tightly connected. In normal 
state, this connection helps maintain optimal homeostasis 
and function of the human body. In pathology, however, 
an affected organ may initiate and perpetuate structural 
and functional dysfunction in other connected organs 
[1, 2]. Thus, acute or chronic heart and kidney diseases 
often coexist in the same patient. Observational studies 
and clinical trials have proven that acute / chronic heart 
disease can directly contribute to acute / chronic kidney 
disease worsening and vice versa. Considering the close and 
bidirectional relationship between these two organs, Acute 
Dialysis Quality Initiative recently proposed a consensus 
definition and classification. The term cardiorenal syndro-
me (CRS) is used to identify cardiac and renal disorders 
as “a complex pathophysiological condition in which acute 
or chronic dysfunction in one organ can cause acute or 
chronic dysfunction in the other” [1].
The prevalence of both heart failure and chronic kidney 
disease in Europe is continuously increasing [2,4,5]. In any 
case / any genesis the association of heart and kidney dys-
function is accompanied by an increased risk of morbidity 
and mortality [4,5].
Classification [1]
Acute cardiorenal syndrome (type 1)
Acute worsening of heart function leading to kidney 
dysfunction and /or damage. This type of injury occurs more 
frequently as a complication of acute heart failure and / or 
acute coronary syndrome. It occurs in 27-40% of patients 
hospitalized with acute heart failure and 70% of patients with 
cardiogenic shock. In these patients morbidity, length of stay 
and mortality increases.
Chronic cardiorenal syndrome (type 2)
Chronic heart disease leading to renal dysfunction or 
injury. This syndrome is frequently encountered, occurs in 
63% of hospitalized patients with congestive heart failure. A 
meta-analytic study focused on the heart failure (IC) - renal 
dysfunction interrelationship reported a prevalence of 63% 
mild and 20% moderate renal impairment. In addition, there 
was a 7% increase in mortality for every decrease in glome-
rular filtration rate (GFR) of 10 mL / min [4].
Acute renocardiac syndrome (type 3)
Acute worsening of renal function leading to cardiac 
dysfunction or damage. The incidence is 10-53%.
Chronic renocardiac syndrome (type 4)
Chronic kidney disease (CKD) leading to heart dysfunc-
tion, injury and/or disease, dysfunction or heart damage. The 
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incidence is unknown and difficult to appreciate (depending 
on primary renal disease incidence), but was noted an incre-
ases by 50% in cardiovascular (CV) mortality. 
Secondary cardiorenal syndrome (type 5)
Systemic diseases leading simultaneously to renal and 
cardiac dysfunction/damage (ex. sepsis, diabetes, lupus 
erythematosus). The incidence and severity depend on sys-
temic disease incidence and severity.
Cardiorenal syndrome (CRS) can be acute, chronic or se-
condary, of cardiac or renal genesis. However, the classification 
is not static, it is generally accepted that patients suffer various 
types of CRS during disease (ex. 12; 34; 2,45) [3] and all 
types are associated with increased mortality and morbidity, 
having a significant impact on health care costs [2, 3].
Epidemiology
CRS syndrome (type 2) occurs when a chronic heart con-
dition leads to chronic renal dysfunction. There are several 
observational studies describing the coexistence of chronic 
heart failure (CHF) and chronic kidney disease (CKD), but 
usually, studies enroll subjects based on the presence of a 
disease (ex.: HF) and describe the prevalence of the other 
(ex.: CKD ) [2, 4].
A meta-analytic study focused on the heart failure (IC) 
- renal dysfunction interrelationship reported a prevalence 
of 63% mild and 20% moderate renal impairment. In addi-
tion, there was a 7% increase in mortality for every decrease 
in glomerular filtration rate (GFR) of 10 mL / min [1,2,4]. 
These types of studies are not able to identify which was the 
primary pathology in order to classify properly the CRS. In 
such cases, the use of the term SCR type 2/4 was suggested [5]. 
Another study focused on congestive heart failure outpatients, 
established severe renal impairment (creatinine clearance ˂ 
30 ml / min) in 39% of the HF patients with functional class 
(FC) IV and 31% of the HF patients with FC III NYHA [5].
A comparative analysis of studies focused on the renal dys-
functions prevalence in HF patients shows the following data:
- The SOLVD study conducted in 2000, on a cohort of 
2161 patients with ejection fraction of 35.7%, recorded 
24.7% cases of renal impairment (GFR <60 mL / min) 
[13];
- The PRIME II study conducted in 2000, on a cohort of 
1906 patients with ejection fraction of 49%, recorded 
26.2% cases of renal impairment (GFR <58ml / min) 
[13];
- The ANCHOR study conducted in 2006, on a cohort of 
59 772 patients, reported 39.2% renal impairment cases 
(GFR 60 mL / min) [14]; 
- The JCARE-CARD study conducted in 2009, on a cohort 
of 2013 patients with ejection fraction of 70.3%, reported 
44.8% cases with renal impairment (GFR 60 mL / min) 
[13,15]; 
In the recent years, the global prevalence of the mode-
rate-severe renal dysfunction gradually increased, up to an 
epidemic state [9.13]. The HF “epidemic” is also increasing 
due to aging and post-myocardial infarction survival impro-
vement [8.10]. The risk of CKD occurrence in heart failure 
is not well-established, but kidney dysfunction is very often 
encountered in HF patients and it is associated with a poor 
prognosis [5,13].
Renal function is a prognostic marker as important as 
ejection fraction and NYHA functional class [5.13].
Pathogenesis
In HF patients who develop renal dysfunction, there are 
intrinsic interactions between these two organs (organic cross 
Fig. 1.  Cardiorenal syndrome mechanisms.
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talk) that could lead to severe complications [1,2,4]. Any HF 
underlying mechanisms, plus existing comorbidities, and / or 
their treatment affect renal function with subsequent renal 
failure development (fig. 1) [1,2,17].
The CRS pathogenesis is multifactorial including struc-
tural lesions caused by atherosclerosis, hemodynamic chan-
ges, neurohormonal and inflammatory components effects 
[1,5,17].
The hypothesis of low cardiac output. Over the past de-
cade, progressive worsening of renal function in HF is consi-
dered as a direct result of the renal flow reduction caused by 
decreased cardiac output. Inadequate afferent renal flow acti-
vates RAAS - leading to volemic retention, increased preload 
and impaired pump function [17]. Recent studies state that, 
although it is correct, this mechanism does not fully explain 
the CRS features. The ESCAPE Study (Evaluation Study of 
Congestive The Failure and Pulmonary Artery Catheteri-
zation Heart Effectiveness) evaluated management through 
guided pulmonary artery catheterization in 400 patients; no 
correlations were found between renal function and cardiac 
index; and, at cardiac index improvement renal function has 
not changed [18], moreover, impaired renal function was 
proven despite the preserved ejection fraction.
The renin-angiotensin-aldosterone system (RAAS) 
activation - RAAS activation at renal perfusion depressi-
on is a protective mechanism in dangerous situations (ex. 
hemorrhage). The chronic stimulation - in heart or renal 
failure, has adverse consequences on both, heart or kidney. 
Angiotensin II has multiple negative effects on the cardi-
ovascular system in HF patients, increases both pre- and 
afterload with a subsequent increase in myocardial oxygen 
demand [1.18]. Angiotensin II activates NADPH oxidase 
in endothelial cells, renal tubules and cardiomyocytes, 
releasing free radicals responsible for aging, inflammation 
and progressive organ dysfunction [1].
Sympathetic nervous system activation (SNS) – SNS 
activation has initially a protective character, overactivation, 
however, reduces the myocardial beta-adrenoreceptors density 
and adrenoreceptors sensitivity both in heart and renal failure 
[17,26]. SNS induces cardiomyocyte apoptosis and increases 
the neuropeptide Y release, which is a promoter of vascular 
growth, accelerates atherosclerosis, induces vasoconstriction 
and interferes with the normal immune system functions.
Intra-abdominal hypertension. HF patients have increased 
central venous pressure, which reduces the renal capillary 
perfusion gradient. It was established that HF patients with 
renal changes had higher central venous pressure than those 
without impaired renal function [17]; also, both high venous 
pressure and jugular pressure correlated with increased cre-
atinine levels [16]. 
Cardiorenal syndrome anemic. Anemia occurs frequently 
in patients with HF and in 30% patients with CRS, being ca-
used by renal and heart failure progression, but also by iron 
deficiency as pointed out the authors of the FAIR-HF study 
(Ferinject Assesmentin Patients with Iron deficiency and 
chronic Heart Failure) [26]. At this time the role and treatment 
of CRS anemia remains controversial.
Diagnosis
The prevalence of symptomatic CHF in the European 
population is 2-3% [8]. The mortality rate increases in concor-
dance with the functional class (CF): 5-10% for CF II, 10-20% 
and 20-40% for CF III and CF IV respectively [10]. For the 
ability to evaluate and compare the patients, it is necessary 
to stratify / divide them by gravity; but because of the CRS 
complexity, until now there was no severity classification con-
sensus and it is recommended to use specific classifications 
for HF (NYHA) and CKD (KDOQI). [1]. 
The diagnosis, prevention and treatment of this syndrome 
are usually fragmented, focused on a single organ and not on 
a multidisciplinary approach. In result, the timing and quality 
of treatment may be affected. In 2010, for the first time the 
ADQI (Acute Dialysis Quality Initiative) consensus group 
comes to define and classify the CRS, to provide standardized 
recommendations for diagnosis (Cystatin C, KIM-1, BNP, 
NT-proBNP, etc.), prevention and management of disease, 
and most importantly, they recommended the cardiologists 
and nephrologists collaboration for the optimization of the 
proposed outcome [1].
The mere coexistence of HF and chronic kidney disease 
is not sufficient for diagnosis. According to the working 
group of the 11th Conference of the Consensus ADQI 
(2013), to confirm CRS type 2 it is necessary: 1) the coe-
xistence of HF and CKD in a patient; 2) temporal causality 
(documented or presumed onset of heart failure precedes 
the onset of kidney damage); and 3) pathophysiological 
plausibility (the manifestation and the degree of renal 
impairment could be explained by the preexisting cardiac 
pathology) [2].
Imaging investigations
Chest X-ray - assesses pulmonary congestion and fluid 
load for the HF severity assessment [19].
Echocardiography - provides information about the heart 
function and anatomy, differentiates preserved or reduced 
ejection fraction HF. Usually echocardiography is sufficient 
as routine imaging diagnostic [17,19].
Fig. 2.  CRS appearance assumptions.  
Reproduced from C. Ronco, 2010 [1].
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Stress echocardiography / PET CT (positron emission 
computed tomography) - assesses the ischemic extent and 
myocardial viability. Limited use because of the high cost [19].
Ultrasonography - assesses renal volume, echogenicity, 
vena cava; contributes to the proper syndrome classification; 
differentiates acute renal failure from chronic kidney disease; 
excludes renal structural pathologies.
Computed tomography and magnetic resonance imaging 
- study the heart function and structure in particular cases 
(usually echocardiography is sufficient), and examine the 
renal vessels.
Cardiac biomarkers
B-type natriuretic peptide (BNP) and the N-terminal 
proBNP (NT-proBNP) are secreted by the heart muscle as 
response to the parietal stress and play an important role in 
the fluid and sodium homeostasis. Volemic loading is the 
most powerful stimulus for the proBNP and BNP secretion 
[1, 2]. The RedHot study (Rapid Emergency Department 
Heart Failure Outpatient Trial) in 2004 showed that natriu-
retic peptides are independent predictors for cardiovascular 
events and mortality in patients with HF [17]. Moreover, their 
prognostic role was reported in patients with different stages 
of renal failure, demonstrating the potential application of 
these markers in type 2 and type 4 cardiorenal syndrome [1.2].
Cardiac troponins - in HF, there is a progressive loss of 
myocytes due to necrosis or apoptosis. Proof of myocyte death 
was obtained by histological studies and, more recently, by tes-
ting troponin (Tn) T and I [1, 25]. These markers can identify 
subclinical myocardial injury. The Vecchis et al. showed an 
increase of TnI in a group of severe non-ischemic HF patients; 
furthermore, they observed a decrease in troponin level at HF 
improvement [3]. Existing studies enrolled relatively small 
groups of patients and excluded patients with severe CKD, 
so the troponin clinical significance in patients with HF and 
severe CKD is not fully clear. Tsutamoto et al. after measuring 
the troponin level difference between caroticus sinus and basal 
aorta; assume that the troponin elevation may be caused by 
glomerular filtration reduction [25].
Highly sensitive troponins - allow HF patients risk stra-
tification. In a cohort of 4053 HF patients TnT was found in 
10.4%, while highly sensitive TnT in 92% patients [25].
Renal biomarkers
Most existing randomized clinical trials (Heywood, 
2007 ADHERE; Cruz, 2010) have focused on mortality 
and cardiovascular events, and only few have examined the 
long-term renal changes occurrence (Capes, 2000; Testani, 
2011) by dynamic evaluation of creatinine, GFR and some of 
inflammatory markers. The prognostic role of renal changes 
(increased creatinine level and / or decreased GFR) in HF was 
demonstrated, it is associated with increased hospitalization 
rate and CV mortality (Jackson, 2009).
Creatinine is an available marker, but may vary up to 
5% throughout the day, has a latency of 2-3 days (changes 
with a delay of 2-3 days), it is influenced by the infections, 
inflammatory processes, meat intake, weight. Measured 
glomerular filtration rate (GFR) may decrease up to 50% 
until the creatinine level reaches the upper limit of normal 
(i.e. estimated GFR will be within normal range). In the 
recent period more sensitive and specific renal biomarkers 
appeared.
Cystatin C - a marker of proximal tubular damage, most 
commonly used for early detection of CKD [1, 2, 11]. It is 
freely filtered in the glomerulus, completely reabsorbed and 
degraded in the tubules, thus its level is considered an ideal 
marker for glomerular filtration rate assessment [3, 25]. 
Most studies suggest that cystatin is not influenced by age, 
sex, muscle mass or diet. It is superior to creatinine in early 
detection of renal damage, preclinical renal disease detection 
or in acute conditions. So far, however, the comparative role 
of cystatin and creatinine in diagnosis / treatment decision 
making in patients with chronic stable or relatively stable HF 
is not established.
KIM-1 (Kidney injury molecule 1) - it is detected in 
proximal tubule epithelial lesions and changes rapidly in 
acute chronic failure; predictor for patients at risk of renal 
function rapid deterioration; decreases after antihypertensive 
Table 1
Proposed definition of CRS2 in stable chronic HF. Reproduced from D. Cruz, 2013 [2]
Chronic HF

EITHER: New onset of CKD
Symptoms typical of HF
Signs typical of HF (HF-REF) Reduced LVEF
OR:
(HF-PEF) Normal or mildly reduced EF and LV not dilated,
with relevant structural disease and/or diastolic
dysfunction (according to ESC, ACC/AHA)
Albuminuria and/or GFR <60 ml/min/1.73m2
(according to KDIGO/KDOQI)
OR: Progression of CKD
Sustained ↓ eGFR of >5 ml/min/1.73m2/year, or >10
ml/min/1.73m2/5 years*
OR: sustained increase in albuminuria
Plus
Temporal association: A documented or presumed onset of congestive heart failure
precedes the occurrence or progression of CKD
Plus
Pathophysiological plausibility: The manifestation and degree of kidney disease is plausibly
explained by the underlying heart condition.
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treatment. There is limited evidence about the KIM-1 value 
in HF patients [1,2].
NAG (N acetyl-beta-D-glucosaminidase) - the enzyme 
formed in the proximal tubule in response to tubular damage. 
It is a sensitive marker of acute renal impairment or renal 
dysfunction worsening. Increases significantly in congestive 
HF, with an important prognostic role independent from the 
glomerular filtration rate [2,24,25].
NGAL (neutrophil-associated lipocalin gelatinase) is 
secreted in the lungs, kidney, trachea, stomach and in the 
colon, thus, it is less specific; it may increase in inflammatory 
processes, sepsis or cancer. It is freely filtered in the glomerulus 
and completely reabsorbed in the proximal tubules. NGAL is 
a marker of renal impairment or acute worsening of renal dys-
function. It increases in HF, without proven prognostic role.
Other markers
Albuminuria- assesses the glomerular permeability.
Interleukin 18 -proinflammatory cytokine, precedes crea-
tinine elevations, but it is secreted less than NGAL. Increases 
in renal failure, but there are not enough studies to prove its 
predictive role in renal function worsening in HF.
High sensitive C-reactive protein - prognostic value in 
cardiovascular disease.
Copeptin- is C-terminal segment of the vasopressin pro-
hormone - important prognostic biomarker in HF, but also 
in albuminuria and renal failure. 
Insulin resistance, leptin, adiponectin, procalcitonin, 
adrenomodulin, interleukin 6, interleukin 1, tumor necrosis 
factor α - are markers with questionable role. 
Because of high cost and limited access to CRS specific 
biomarkers; because of the serious damage they cause (incre-
ased post-myocardial infarction mortality) occurs the need to 
highlight predisposing factors (hypertension, diabetes, obesity 
and metabolic diseases, cachexia, renal disease, preexisting 
proteinuria, uremia, anemia, chemotherapy, mineral and 
bone deficiencies, electrolyte and acid-base imbalances, etc.)
Treatment
Treatment is complex and incompletely defined [2]. Accu-
rate HF treatment is essential to reduce or eliminate the causes 
that led to the appearance / progression of renal dysfunction.
Diuretics
Hypervolaemia is the most pre-eminent CRS manifes-
tation. Normalization of the fluid status may be achieved 
by sodium reduction or diuretics use. Although for long 
diuretics were considered the essential strategy in this syn-
drome, there is little data to confirm their beneficial effect on 
mortality. ADHERE registry data reported that 81% patients 
with acute HF, were receiving chronic diuretic treatment at 
admission. Other studies have shown a decreased glome-
rular filtration rate due to furosemide [4], and increased 
cardiovascular mortality [23]. Marker of poor prognosis in 
patients with HF can be considered diuretic resistance, most 
likely caused by inadequate doses of diuretics, high sodium 
intake, slowing diuretics intestinal absorption because of the 
intestinal mucosa edema, reduced diuretic clearance [25, 
26] or concomitant NSAIDs administration by decreasing 
natriuretic and vasodilating prostaglandin synthesis [4]. In 
such cases: 1) furosemide dosage should be increased, not 
the administration frequency; 2) to avoid low absorption and 
bioavailability, diuretics will be administered intravenous. A 
Cochrane review article confirms that the diuresis obtained 
at intravenous continuously with furosemide administration 
is superior to that obtained at bolus administration; they also 
noted a reduction in the mortality and length of stay. Other 
options are thiazides or low salt content albumin supplemen-
tation to increase sodium excretion.
Vasodilators. Intravenous nitroglycerin or nesiritide (re-
combinant human type B atrial natriuretic peptide).
Kidney detrimental effects are lower than those of diuretics 
are. Vasodilators rapidly decline central venous pressure and 
decrease myocardial oxygen demand without blood pressure 
lowering (in small doses), may decrease systemic vascular 
resistance, left ventricular pressure, and improve cardiac ou-
tput. Central venous pressure reduction may decrease renal 
perfusion pressure, but long-term effect on renal function and 
survival is not known [25].
Angiotensin-converting enzyme (ACE) inhibitors
ACE are known to reduce HF patients’ mortality [13], but 
most of these studies have excluded moderate-severe renal 
impairment patients [21]. The CONSENSUS study (Coope-
rative North Scandinavian Enalapril Survival) demonstrated 
that in patients with moderate renal impairment upon the 
enalapril initiation creatinine levels substantially increased. 
Despite initial growth of creatinine in some of these patients 
improved long term prognosis was noted, therefore ACE 
should not be excluded, but should be administered with 
caution and with close renal function monitoring during the 
treatment initiation and titration[4 ].
Beta blockers
Although they have a role in HF by decreasing sympathetic 
activity, their use in CRS is limited because of the hemodyna-
mic changes. When the patient is stabilized, it can re-initiate 
its administration in low doses [17].
Positive inotropic support - controversial
Albeit is known that Milrinone, Levosimendan and Do-
pamine improve cardiac index and in “renal” (small) doses 
increase renal perfusion, the OPTIME-HF trial (The Outcome 
Of A Prospective Trial of Intravenous Milrinone for exacerba-
tions for Chronic Heart Failure) demonstrated their beneficial 
effects on renal flow and cardiac output, however they do not 
influence the mortality [4.26].
Statins
Are used for lipid lowering effect, but also for endothelial 
function improvement by increasing the nitric oxide availabi-
lity, reducing vascular inflammation and oxidative stress [17].
Vasopressin antagonists
Vasopressin, by coupling to specific receptor V1a (vascular) 
and V2 (renal), induces vasoconstriction and water absorption. 
The selective antagonists V2 (Tolvaptan) activates the free water 
clearance. The EVEREST study (Efficacy of vasopressin antago-
nist Failure Outcome Study with Tolvaptan Heart) part of the 
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ACTIV research has confirmed the early beneficial effect in acute 
HF patients, although on long term there were not significant 
differences compared to placebo [26].
Adenosine antagonists
There are new agents that promote diuresis by coupling 
with A1 receptors, it may improve renal blood flow and in-
crease sodium excretion [24, 26]. The efficacy and safety of 
the medication is being assessed.VVV
Ultrafiltration
It is a method increasingly used in HF patients. The amount 
of sodium and water removed by ultrafiltration is much higher 
than that eliminated by forced diuresis, it further decreases the 
hospitalization length, decreases mortality and rehospitalization 
rate [4.24]. The ultrafiltration decreases right atrial and pulmo-
nary artery pressure, improves cardiac output and gas exchange. 
However, aggressive ultrafiltration, can convert a non- oliguric 
renal dysfunction in oliguric renal insufficiency.
The renal impairment worsening may require calcium, 
vitamin D agonists, iron or erythropoietin administration.
Unsolved problems
While remarkable progress has been made in the cardiorenal 
syndrome understanding, it is necessary to implement new bio-
markers that would allow early diagnosis before the appearance 
of kidney irreversible changes, in order to slowdown the cardi-
orenal complications progression in CHF patients with adverse 
impact on length and quality of life. Also, there are no criteria 
for severity and evolution assessment in cardiorenal syndrome; 
in clinical practice renal impairment severity within cardiorenal 
syndrome is assessed according to the KDOQI classification and 
heart failure according to NYHA criteria.
There are multiple studies that assess the coexistence of HF 
and kidney disease, but there are no clear, objective (other than 
chronological) criteria that may differentiate type 2 from type 
4 cardiorenal syndrome. Usually, such studies enroll patients 
admitted to a cardiology ward or who address the cardiologist 
and were conventionally considered as having primary cardiac 
pathology, i.e. type 2 CRS; if the same patient addressed the 
nephrologist he could be conventionally considered as having 
primary renal disease, respectively CRS type 4. Therefore, the 
study accuracy may be affected. A possible solution would be 
the start of a long-term prospective project with enrollment 
and monitoring of HF FC I-II NYHA patients, without other 
comorbidities or renal function impaired. From our best 
knowledge up to this moment, there are no such studies; the 
present studies used only chronological criteria.
CRS treatment involves the use of diuretics, vasodilators, 
ultrafiltration; all these options provide rapid volemic decline, 
but until now, their real impact on renal function and survival 
is not known.
It requires further research to determine effective, safe and 
cost-efficient therapeutic strategies.
It was determined that when the treatment is fragmented 
on pathologies, the patient’s condition worsens: intensive 
treatment with loop diuretics for heart failure worsens renal 
dysfunction; angiotensin converting enzyme, spironolactone 
or vasodilators treatment, may also aggravate renal dysfunc-
tion; on the other hand, renal failure may affect the drugs 
clearance with the need of dosage review [1, 3]. To achieve 
a common goal – patient's safety, in clinical practice colla-
boration of cardiologists, nephrologists and internists is of 
utmost importance.
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